A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Seminars in liver disease Pub Date : 2022-05-01 DOI:10.1055/a-1777-6112

Jeffrey V Lazarus, Camila A Picchio, Christopher J Byrne, Javier Crespo, Massimo Colombo, Graham S Cooke, Gregory J Dore, Jason Grebely, John W Ward, John F Dillon

{"title":"A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination.","authors":"Jeffrey V Lazarus, Camila A Picchio, Christopher J Byrne, Javier Crespo, Massimo Colombo, Graham S Cooke, Gregory J Dore, Jason Grebely, John W Ward, John F Dillon","doi":"10.1055/a-1777-6112","DOIUrl":null,"url":null,"abstract":"<p><p>Microelimination targets specific subpopulations and/or geographic settings for hepatitis C virus (HCV) elimination. This review reports on global HCV microelimination literature published from 2013 to 2020. Data were extracted from publications to report a score based on the four key components defining microelimination. Sustained virologic response (SVR) and treatment initiation proportions were calculated for each manuscript and grouped means of these estimates were compared depending on microelimination score and care setting. A total of 83% of the studies were from high-income settings and mainly included people who use drugs or those incarcerated. Among manuscripts, 18 had \"low\" microelimination scores, 11 had \"high\" scores, and the differences in mean proportion who initiated treatment and achieved SVR between low and high score groups were statistically significant. Microelimination can be a useful complementary strategy for driving engagement in HCV treatment and cure. Our analysis suggests that adhering to more of the core microelimination components can improve outcomes. This study is registered with Prospero, registration identification: CRD42020175211.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"42 2","pages":"159-172"},"PeriodicalIF":4.3000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in liver disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1777-6112","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 14

Abstract

Microelimination targets specific subpopulations and/or geographic settings for hepatitis C virus (HCV) elimination. This review reports on global HCV microelimination literature published from 2013 to 2020. Data were extracted from publications to report a score based on the four key components defining microelimination. Sustained virologic response (SVR) and treatment initiation proportions were calculated for each manuscript and grouped means of these estimates were compared depending on microelimination score and care setting. A total of 83% of the studies were from high-income settings and mainly included people who use drugs or those incarcerated. Among manuscripts, 18 had "low" microelimination scores, 11 had "high" scores, and the differences in mean proportion who initiated treatment and achieved SVR between low and high score groups were statistically significant. Microelimination can be a useful complementary strategy for driving engagement in HCV treatment and cure. Our analysis suggests that adhering to more of the core microelimination components can improve outcomes. This study is registered with Prospero, registration identification: CRD42020175211.

查看原文本刊更多论文

通过微消除消除丙型肝炎努力的全球系统综述。

微消除针对消除丙型肝炎病毒(HCV)的特定亚群和/或地理环境。本综述报告了2013年至2020年全球HCV微消除文献。从出版物中提取数据，根据定义微消除的四个关键组成部分报告得分。计算每份手稿的持续病毒学应答(SVR)和治疗起始比例，并根据微消除评分和护理环境比较这些估计值的分组平均值。总共83%的研究来自高收入环境，主要包括吸毒者或被监禁的人。微消除评分“低”的有18篇，“高”的有11篇，低评分组和高评分组开始治疗并达到SVR的平均比例差异有统计学意义。微消除可作为推动参与丙型肝炎病毒治疗和治愈的有益补充策略。我们的分析表明，坚持更多的核心微消除成分可以改善结果。本研究注册在普洛斯彼罗，注册号:CRD42020175211。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in liver disease 医学-胃肠肝病学

CiteScore

8.20

自引率

2.40%

发文量

期刊介绍： Seminars in Liver Disease is a quarterly review journal that publishes issues related to the specialties of hepatology and gastroenterology. As the premiere review journal in the field, Seminars in Liver Disease provides in-depth coverage with articles and issues focusing on topics such as cirrhosis, transplantation, vascular and coagulation disorders, cytokines, hepatitis B & C, Nonalcoholic Steatosis Syndromes (NASH), pediatric liver diseases, hepatic stem cells, porphyrias as well as a myriad of other diseases related to the liver. Attention is also given to the latest developments in drug therapy along with treatment and current management techniques. Seminars in Liver Disease publishes commissioned reviews. Unsolicited reviews of an exceptional nature or original articles presenting remarkable results will be considered, but case reports will not be published.